Search research articles
Contact Us
Filters
Showing results (181-190 of 203) with videos related to
Page
of 21
Sort By:
Biorxiv : the Preprint Server for Biology
|
October 28, 2024
Retinoid X Receptor Signaling Mediates Cancer Cell Lipid Metabolism in the Leptomeninges
Xinran Tong, Jan Remsik, Jeanette Brook, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 2, 2017
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity
Natasha Lewis, Robert A Soslow, Deborah F Delair, et al.
Gynecologic Oncology
|
February 24, 2021
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer
Arnaud Da Cruz Paula, Deborah F DeLair, Lorenzo Ferrando, et al.
Nature Genetics
|
September 8, 2015
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
A Hunter Shain, Maria Garrido, Thomas Botton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 25, 2021
TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition
Sarah Chiang, Varshini Vasudevaraja, Jonathan Serrano, et al.
British Journal of Cancer
|
March 20, 2008
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
P M O'Brien, M J Davies, J P Scurry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2014
Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant
Kasmintan A Schrader, Kelly L Stratton, Rajmohan Murali, et al.
Page
of 21
Search research articles
Search
Showing results (181-190 of 203) with videos related to
Sort By:
Page
of 21
Biorxiv : the Preprint Server for Biology
|
October 28, 2024
Retinoid X Receptor Signaling Mediates Cancer Cell Lipid Metabolism in the Leptomeninges
Xinran Tong, Jan Remsik, Jeanette Brook, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
December 2, 2017
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity
Natasha Lewis, Robert A Soslow, Deborah F Delair, et al.
Gynecologic Oncology
|
February 24, 2021
Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer
Arnaud Da Cruz Paula, Deborah F DeLair, Lorenzo Ferrando, et al.
Nature Genetics
|
September 8, 2015
Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway
A Hunter Shain, Maria Garrido, Thomas Botton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 25, 2021
TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition
Sarah Chiang, Varshini Vasudevaraja, Jonathan Serrano, et al.
British Journal of Cancer
|
March 20, 2008
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
P M O'Brien, M J Davies, J P Scurry, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 2, 2014
Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant
Kasmintan A Schrader, Kelly L Stratton, Rajmohan Murali, et al.
Page
of 21